Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 145,190 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Recruiting Phase 3 Interventional

Sevoflurane/Dexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium

NCT06624592
View directory record Official record
Conditions
Delirium on Emergence
Interventions
Sevoflurane, Isoflurane
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 7 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 29, 2026, 3:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

NCT06785636
View directory record Official record
Conditions
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
Interventions
Pocenbrodib, Pocenbrodib and Darolutamide
Drug
Lead sponsor
Pathos AI, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

NCT06136936
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156-C-001
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 29, 2026, 3:10 PM EDT
Completed No phase listed Observational

Long-term Observation of Patients With Early Rheumatoid Arthritis

NCT00240136
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 29, 2026, 3:10 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

NCT02909036
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis
Interventions
Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
Device · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 3:10 PM EDT
Enrolling by invitation Phase 2 Interventional

Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia

NCT06148311
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Matching placebo, Dexmedetomidine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 29, 2026, 3:10 PM EDT
Recruiting Not applicable Interventional

Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD

NCT05929911
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), HIV
Interventions
Trauma-focused psychodynamic psychotherapy
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

NCT00107211
View directory record Official record
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, conventional surgery, neoadjuvant therapy
Biological · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 2 Interventional

Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

NCT00005811
View directory record Official record
Conditions
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, HIV-associated Hodgkin Lymphoma, Leptomeningeal Metastases, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 29, 2026, 3:10 PM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Oct 29, 2026, 3:10 PM EDT
Completed No phase listed Observational

Atrial Fibrillation/Flutter Outcome Risk Determination

NCT01138644
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

NCT00001444
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
Interventions
7-hydroxystaurosporine (UCN-01)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Not applicable Interventional Results available

Telemedicine Optimized Burn Intervention

NCT05019144
View directory record Official record
Conditions
Burns, Pediatric ALL
Interventions
Face-to-face burn care, Telemedicine enhanced burn care
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
0 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Not applicable Interventional

Smart Sleep In-home Validation Extension Study

NCT03665844
View directory record Official record
Conditions
Healthy, Sleep Deprivation, Insufficient Sleep Syndrome
Interventions
SmartSleep Boost On, SmartSleep Boost Off
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lehigh Acres, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

NCT02933034
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Investigation Examining Plaque and Gingivitis Connected Toothbrush Compared to Non-Connected Toothbrush

NCT04221334
View directory record Official record
Conditions
Gingivitis, Plaque, Dental
Interventions
Electric Toothbrush, oral health care application
Device · Other
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 29, 2026, 3:10 PM EDT
Completed No phase listed Observational

Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice

NCT02277834
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 3 Interventional

Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer

NCT00244309
View directory record Official record
Conditions
Prostate Cancer
Interventions
tamsulosin and/or dutasteride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2016 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 29, 2026, 3:10 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Lung Allograft Rejection Gene Expression Observational (LARGO) Study

NCT00751309
View directory record Official record
Conditions
Graft Rejection, Lung Disease
Interventions
Non-interventional
Other
Lead sponsor
XDx
Industry
Eligibility
Not listed
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2008 · Synced Oct 29, 2026, 3:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

NCT04690699
View directory record Official record
Conditions
Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
Interventions
Lerapolturev, 5% DDM
Biological · Other
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Myrtle Beach, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 1 Interventional

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

NCT00000899
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 29, 2026, 3:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 29, 2026, 3:10 PM EDT